siponimod
Sign in to saveAlso known as BAF312, Mayzent
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
Research
370 papers- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.Lancet (London, England) · 2018
- Siponimod.2012
- Siponimod for multiple sclerosis.The Cochrane database of systematic reviews · 2021
- Siponimod.2006
- Siponimod to treat secondary progressive multiple sclerosis.Drugs of today (Barcelona, Spain : 1998) · 2020
via PubMed
~5 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- History
- References
{{Infobox drug | image = Siponimod.svg | image_class = skin-invert-image | width = 275 | alt = | caption =
| pronounce = | tradename = Mayzent | Drugs.com = | MedlinePlus = a619027 | DailyMedID = Siponimod | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L04 | ATC_suffix = AE03 | ATC_supplemental =
Excerpted from Wikipedia’s “siponimod” article, available under the CC BY-SA 4.0 licence.